Dr. Reddy's Laboratories Limited informed that the Company enters into exclusive distribution partnership with Sanofi Healthcare India Private Limited to promote and distribute the vaccine brands of SHIPL including well-established paediatric and adult vaccines, in India. Domestic/international: Domestic - India. Scope of business operation of agreement: Exclusive rights to promote and distribute the vaccine brands of SHIPL including well- established paediatric and adult vaccines.

The vaccine brands saw combined sales of approx. INR 4,260 million (approx. USD 51 million) as per IQVIA Moving Annual Total (MAT) February 2024.

Details of consideration paid/received in agreement: There is no upfront payment involved in this arrangement. Under this arrangement, SHIPL shall supply to the Company and the Company shall purchase from SHIPL, the vaccine brands of SHIPL including well-established paediatric and adult vaccines for promoting and distributing the same in private markets in India. Significant terms and conditions of agreement: Under the arrangement, the Company will have exclusive rights to promote and distribute Sanofi's well-established and trusted vaccine brands Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri, Adacel and Avaxim 80U.

Rationale and benefit expected: The partnership continues the Company's efforts to become the partner of choice in increasing access to novel, innovative as well as trusted drugs for patients. The partnership gives the Company a strong portfolio and major presence in the vaccine segment in India, taking it to second position among vaccine players in India (as per IQVIA MAT February 2024).